18FDG PET/CT标准摄取值与非小细胞肺癌临床分期关系的研究

目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者治疗前的18氟脱氧葡萄糖(18F-deoxyglucose,18 FDG) PET／CT标准摄取值(standard uptake value, SUV)与临床分期、原发肿瘤大小及病理学类型的关系。方法:对75例治疗前的NSCLC患者接受18FDG PET／CT检查获得最高SUV (SUVmax)。分析SUVmax与临床分期、原发肿瘤分期、肿瘤大小和病理学类型的关系,并研究SUV在四者组内差异是否有统计学意义。结果:SUVmax与临床分期和原发肿瘤大小均呈正相关(r=0．279,P=0．014;r= 0．645,P=0．001),与肿瘤病理学类型无关(r=-0．077,P=0．507);SUV在两组不同大小肿瘤组(≤3．0 cm和>3．0 cm)间差异有统计学意义,t=-0．647,P=0．015,在各个临床分期组(ⅠA～ⅡB、ⅢA和m B～Ⅳ)间差异有统计学意义,F=3．807,P=0．027,在4个原发肿瘤分期组(T1、T2、T3和T4)间差异有统计学意义,F=8．025,P=0．022,而在不同病理学类型组(鳞癌、腺癌和腺鳞癌)间差异无统计学意义,F=1．911,P=0．155。结论:18FDG PET／CT SUV随肿瘤大小和病期的增加呈升高趋势,可以作为评价NSCLC临床分期的辅助手段,但不能为无法取得病理学诊断的患者提供帮助。

Correlation between standard uptake value of 18FDG PET/CT and clinical staging of non-small cell lung cancer

OBJECTIVE: To investigate the correlation between standard uptake value (SUV) of 18F-fluorodeoxygluco.se Positron Emission Tomography (18FDG PET/CT) and the clinical staging, primary tumor size, pathological type of non-small cell lung cancer (NSCLC) patients who received the examination of 18FDG PET/CT before the treatment. METHODS:75 patients with biopsy-proven NSCLC were included in the protocol. All cases had whole body 18FDG PET/CT scans prior to the treatment. Maximal SUVs (SUVmax) which were obtained by selecting a small region of interest (ROI) were used in the analysis. RESULTS:Clinical staging was positively related to SUV, r = 0.279, P = 0. 014;SUVs were obviously different among the three clinical staging groups by single factor analysis of variance, F = 3. 807, P = 0. 027. The correlation between SUV and the two groups standed for primary tumor size were observed, r=0. 645, P = 0. 001. Independent t-test showed that there were significant differences in SUV between the two groups, t= - 0. 647, P = 0. 015. Single factor analysis of variance showed that SUVs were different among four T staging groups, F=8. 025, P= 0.022. However, the correlation between SUV and pathological type had no statistical difference, r= -0.077, P=0. 507, and single factor analysis of variance demonstrated adverse outcome among the pathological type groups, F= 1. 911, P = 0. 155. CONCLUSIONS: Both primary tumor size and clinical staging of NSCLC can be evaluated by 18FDG PET/CT SUV, but pathological type of NSCLC is not related to SUV.